Impacts of global change on species distributions: obstacles and solutions to integrate climate and land use

Aim The impact of multiple stressors on biodiversity is one of the most pressing questions in ecology and biodiversity conservation. Here we critically assess how often and efficiently two main drivers of global change have been simultaneously integrated into research, with the aim of providing practical solutions for better integration in the future. We focus on the integration of climate change (CC) and land-use change (LUC) when studying changes in species distributions. Location Global. Methods We analysed the peer-reviewed literature on the effects of CC and LUC on observed changes in species distributions, i.e. including species range and abundance, between 2000 and 2014. Results Studies integrating CC and LUC remain extremely scarce, which hampers our ability to develop appropriate conservation strategies. The lack of CC-LUC integration is likely to be a result of insufficient recognition of the co-occurrence of CC and LUC at all scales, covariation and interactions between CC and LUC, as well as correlations between species thermal and habitat requirements. Practical guidelines for the study of these interactive effects include considering multiple drivers and processes when designing studies, using available long-term datasets on multiple drivers, revisiting single-driver studies with additional drivers or conducting comparative studies and meta-analyses. Combining various methodological approaches, including time lags and adaptation processes, represent further avenues to improve global change science. Main conclusions Despite repeated claims for a better integration of multiple drivers, the effects of CC and LUC on species distributions and abundances have been mostly studied in isolation, which calls for a shift of standards towards more integrative global change science. The guidelines proposed here will encourage study designs that account for multiple drivers and improve our understanding of synergies or antagonisms among drivers

A resource-based modelling framework to assess habitat suitability for Steppe birds in semiarid Mediterranean agricultural systems

European agriculture is undergoing widespread changes that are likely to have profound impacts on farmland biodiversity. The development of tools that allow an assessment of the potential biodiversity effects of different land-use alternatives before changes occur is fundamental to guiding management decisions. In this study, we develop a resource-based model framework to estimate habitat suitability for target species, according to simple information on species’ key resource requirements (diet, foraging habitat and nesting site), and examine whether it can be used to link land-use and local species’ distribution. We take as a study case four steppe bird species in a lowland area of the north-eastern Iberian Peninsula. We also compare the performance of our resource-based approach to that obtained through habitat-based models relating species’ occurrence and land-cover variables. Further, we use our resource-based approach to predict the effects that change in farming systems can have on farmland bird habitat suitability and compare these predictions with those obtained using the habitat-based models. Habitat suitability estimates generated by our resource-based models performed similarly (and better for one study species) than habitat based-models when predicting current species distribution. Moderate prediction success was achieved for three out of four species considered by resource-based models and for two of four by habitat-based models. Although, there is potential for improving the performance of resource-based models, they provide a structure for using available knowledge of the functional links between agricultural practices, provision of key resources and the response of organisms to predict potential effects of changing land-uses in a variety of context or the impacts of changes such as altered management practices that are not easily incorporated into habitat-based models

Changes in the content of chlorophylls and carotenoids in the rind of Fino 49 lemons during maturation and their relationship with parameters from the CIELAB color space

In the present work, the coordinates L*, a* and b* from the CIELAB color space, as well as the chlorophyll, total carotenoids and the content of the carotenoids Lutein and β-cryptoxanthin were measured in the skin of fruits from the Fino 49 lemon during its development, with the aim of understanding the relationship that exists between the color changes of the fruit’s skin (color coordinates) and the pigment content. Also, the understanding of the relative importance of the contents of lutein and β-cryptoxanthin with respect to the total content of carotenoids was sought. The period of study lasted three years; from September 2015 to January 2016, from September 2016 to January 2017, and from September 2017 to January 2018, the periods that comprised the color changes of the lemon fruit until its harvest. The fruits were measured every two weeks in the experimental plot of the IMIDA (Murcian Institute of Agricultural and Food Research and Development) located at La Alberca (Murcia, Spain) and in the experimental orchards from the CEBAS-CSIC, located in Santomera (Murcia). During he experiment, the color and chlorophyll, Lutein and β-cryptoxanthin concentrations were measured. The results showed that there was a good correlation between the color coordinates and the pigments responsible for the lemon’s skin color: all the color pigments were correlated with the a*, b* color coordinates and the Hue angle index. Throughout the fruit’s maturation, a degradation of the chlorophylls was observed, as well as an increase of β-cryptoxanthin, which is responsible for the green and yellow color of the fruits, respectively. Lutein, which was found in high concentrations, decreased with time, but did not contribute to the fruit’s color

An assessment of relative habitat use as a metric for species' habitat association and degree of specialization

Corrigendum: Ecological Indicators, Volume 137, April 2022, Article number 108627, https://doi.org/10.1016/j.ecolind.2022.108627.In order to understand species' sensitivity to habitat change, we must correctly determine if a species is associated with a habitat or not, and if it is associated, its degree of specialization for that habitat. However, definitions of species' habitat association and specialization are often static, categorical classifications that coarsely define species as either habitat specialists or generalists and can fail to account for potential temporal or spatial differences in association or specialization. In contrast, quantitative metrics can provide a more nuanced assessment, defining species' habitat associations and specialization along a continuous scale and accommodate for temporal or spatial variation, but these approaches are less widely used. Here we explore relative habitat use (RHU) as a metric for quantifying species' association with and degree of specialization for different habitat types. RHU determines the extent of a species' association with a given habitat by comparing its abundance in that habitat relative to its mean abundance across all other habitats. Using monitoring data for breeding birds across Europe from 1998 to 2017; we calculate RHU scores for 246 species for five habitat types and compared them to the literature-based classifications of their association with and specialization for each of these habitats. We also explored the temporal variation in species' RHU scores for each habitat and assessed how this varied according to association and degree of specialization. In general, species' RHU and literature-derived classifications were well aligned, as RHU scores for a given habitat increased in line with reported association and specialization. In addition, temporal variation in RHU scores were influenced by association and degree of specialization, with lower scores for those associated with, and those more specialized to, a given habitat. As a continuous metric, RHU allows a detailed assessment of species' association with and degree of specialization for different habitats that can be tailored to specific temporal and/or spatial requirements. It has the potential to be a valuable tool for identifying indicator species and in supporting the design, implementation and monitoring of conservation management actions.Peer reviewe

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

Background: The phase III CLinical Evaluation Of Pertuzumab And TRAstuzumab (CLEOPATRA) trial established the combination of pertuzumab, trastuzumab and docetaxel as standard first-line therapy for human epidermal growth factor receptor 2 (HER2)-positive locally recurrent/metastatic breast cancer (LR/mBC). The multicentre single-arm PERtUzumab global SafEty (PERUSE) study assessed the safety and efficacy of pertuzumab and trastuzumab combined with investigator-selected taxane in this setting. Patients and methods: Eligible patients with inoperable HER2-positive LR/mBC and no prior systemic therapy for LR/mBC (except endocrine therapy) received docetaxel, paclitaxel or nab-paclitaxel with trastuzumab and pertuzumab until disease progression or unacceptable toxicity. The primary endpoint was safety. Secondary endpoints included progression-free survival (PFS) and overall survival (OS). Prespecified subgroup analyses included subgroups according to taxane, hormone receptor (HR) status and prior trastuzumab. Exploratory univariable analyses identified potential prognostic factors; those that remained significant in multivariable analysis were used to analyse PFS and OS in subgroups with all, some or none of these factors. Results: Of 1436 treated patients, 588 (41%) initially received paclitaxel and 918 (64%) had HR-positive disease. The most common grade 653 adverse events were neutropenia (10%, mainly with docetaxel) and diarrhoea (8%). At the final analysis (median follow-up: 5.7 years), median PFS was 20.7 [95% confidence interval (CI) 18.9-23.1] months overall and was similar irrespective of HR status or taxane. Median OS was 65.3 (95% CI 60.9-70.9) months overall. OS was similar regardless of taxane backbone but was more favourable in patients with HR-positive than HR-negative LR/mBC. In exploratory analyses, trastuzumab-pretreated patients with visceral disease had the shortest median PFS (13.1 months) and OS (46.3 months). Conclusions: Mature results from PERUSE show a safety and efficacy profile consistent with results from CLEOPATRA and median OS exceeding 5 years. Results suggest that paclitaxel is a valid alternative to docetaxel as backbone chemotherapy. Exploratory analyses suggest risk factors that could guide future trial design

Why Are Outcomes Different for Registry Patients Enrolled Prospectively and Retrospectively? Insights from the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF).

Background: Retrospective and prospective observational studies are designed to reflect real-world evidence on clinical practice, but can yield conflicting results. The GARFIELD-AF Registry includes both methods of enrolment and allows analysis of differences in patient characteristics and outcomes that may result. Methods and Results: Patients with atrial fibrillation (AF) and ≥1 risk factor for stroke at diagnosis of AF were recruited either retrospectively (n = 5069) or prospectively (n = 5501) from 19 countries and then followed prospectively. The retrospectively enrolled cohort comprised patients with established AF (for a least 6, and up to 24 months before enrolment), who were identified retrospectively (and baseline and partial follow-up data were collected from the emedical records) and then followed prospectively between 0-18 months (such that the total time of follow-up was 24 months; data collection Dec-2009 and Oct-2010). In the prospectively enrolled cohort, patients with newly diagnosed AF (≤6 weeks after diagnosis) were recruited between Mar-2010 and Oct-2011 and were followed for 24 months after enrolment. Differences between the cohorts were observed in clinical characteristics, including type of AF, stroke prevention strategies, and event rates. More patients in the retrospectively identified cohort received vitamin K antagonists (62.1% vs. 53.2%) and fewer received non-vitamin K oral anticoagulants (1.8% vs . 4.2%). All-cause mortality rates per 100 person-years during the prospective follow-up (starting the first study visit up to 1 year) were significantly lower in the retrospective than prospectively identified cohort (3.04 [95% CI 2.51 to 3.67] vs . 4.05 [95% CI 3.53 to 4.63]; p = 0.016). Conclusions: Interpretations of data from registries that aim to evaluate the characteristics and outcomes of patients with AF must take account of differences in registry design and the impact of recall bias and survivorship bias that is incurred with retrospective enrolment. Clinical Trial Registration: - URL: http://www.clinicaltrials.gov . Unique identifier for GARFIELD-AF (NCT01090362)

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362